Last Updated: November 9, 2026

Details for Patent: 11,426,348

« Back to Dashboard


Which drugs does patent 11,426,348 protect, and when does it expire?

Patent 11,426,348 protects EXPAREL and is included in one NDA.

This patent has thirteen patent family members in seven countries.

Summary for Patent: 11,426,348
Title:Compositions of bupivacaine multivesicular liposomes
Abstract:Embodiments of the present application relate to compositions of multivesicular liposomes (MVLs) and commercial manufacturing processes for making bupivacaine MVLs.
Inventor(s):Jeffrey S. Hall, David J. Turnbull, John J. Grigsby, Jr., Soroush M. Ardekani, Kathleen D. A. Los
Assignee: Pacira Pharmaceuticals Inc
Application Number:US17/590,636
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 11,426,348
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 11,426,348

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pacira Pharms Inc EXPAREL bupivacaine INJECTABLE, LIPOSOMAL;INJECTION 022496-001 Oct 28, 2011 RX Yes Yes 11,426,348 ⤷  Start Trial Y METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA ⤷  Start Trial
Pacira Pharms Inc EXPAREL bupivacaine INJECTABLE, LIPOSOMAL;INJECTION 022496-002 Oct 28, 2011 RX Yes Yes 11,426,348 ⤷  Start Trial Y METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,426,348

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 114209654 ⤷  Start Trial
Denmark 4032528 ⤷  Start Trial
European Patent Office 4032528 ⤷  Start Trial
European Patent Office 4740937 ⤷  Start Trial
Spain 3073947 ⤷  Start Trial
Finland 4032528 ⤷  Start Trial
United Kingdom 202200778 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.